Cart
sales@molnova.com
Isosilybin B
CAS No. 142796-22-3
Isosilybin B( —— )
Catalog No. M31844 CAS No. 142796-22-3
Isosilybin B is a flavonolignan extracted from silymarin that exhibits anti-prostate cancer (PCA) activity, inhibits cancer cell proliferation, and contributes to G1-phase blockade and apoptosis.Isosilybin B induces degradation of the androgen receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 425 | In Stock |
|
| 10MG | 610 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
Biological Information
-
Product NameIsosilybin B
-
NoteResearch use only, not for human use.
-
Brief DescriptionIsosilybin B is a flavonolignan extracted from silymarin that exhibits anti-prostate cancer (PCA) activity, inhibits cancer cell proliferation, and contributes to G1-phase blockade and apoptosis.Isosilybin B induces degradation of the androgen receptor.
-
DescriptionIsosilybin B is a flavonolignan extracted from silymarin that exhibits anti-prostate cancer (PCA) activity, inhibits cancer cell proliferation, and contributes to G1-phase blockade and apoptosis.Isosilybin B induces degradation of the androgen receptor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number142796-22-3
-
Formula Weight482.4
-
Molecular FormulaC25H22O10
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Dihydromyricetin
Dihydromyricetin is a potent inhibitor of dihydropyrimidinase with an IC50 of 48 μM. Dihydromyricetin can activate autophagy by inhibiting mTOR signaling.
-
PSA1 141-150
This Prostate Specific Antigen 1 peptide was used in the immunotherapy of cancer experiments.
-
NLS-StAx-h
Wnt inhibitor (IC50 = 1.4 μM). Stapled peptide inhibitor of oncogenic Wnt signaling. Inhibits β-catenin-transcription factor interactions. Inhibits proliferation and migration of colorectal cancer cells. Cell permeable.
